Badanie nad przewlekłą białaczką limfocytową i chłoniakiem limfocytowym z użyciem ibrutynibu i wenetoklaksu dla pacjentów z nowo zdiagnozowaną chorobą

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are types of cancer that affect the blood and lymph nodes. These diseases often require treatment to manage symptoms and slow progression. A study is being conducted to compare two different treatment combinations for these conditions. The first combination includes ibrutinib and venetoclax, while the second combination includes chlorambucil and obinutuzumab. Ibrutinib is taken in the form of a capsule, and it works by blocking certain proteins that help cancer cells grow. Venetoclax is another medication that targets cancer cells, while chlorambucil and obinutuzumab are used to treat blood cancers by attacking cancer cells in different ways.

The purpose of this study is to see which treatment combination is more effective in preventing the cancer from getting worse. Participants in the study will be randomly assigned to receive one of the two treatment combinations. The study will monitor how long the cancer stays under control without worsening, which is known as progression-free survival. This will be assessed by an independent group of experts. The study is designed to provide important information about the effectiveness of these treatments for people with CLL or SLL.